Last reviewed · How we verify
MSDC-0160
At a glance
| Generic name | MSDC-0160 |
|---|---|
| Also known as | Mitoglitazone |
| Sponsor | Metabolic Solutions Development Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients (PHASE2)
- 3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease (PHASE2)
- A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MSDC-0160 CI brief — competitive landscape report
- MSDC-0160 updates RSS · CI watch RSS
- Metabolic Solutions Development Company portfolio CI